citalopram has been researched along with Cardiotoxicity in 2 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Citalopram treatment was associated with a larger increase in QTc interval than placebo (difference in week 3 QTc adjusting for baseline QTc: 18." | 2.79 | Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. ( Devanand, DP; Drye, LT; Frangakis, C; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Spragg, D; Weintraub, D; Yesavage, J, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Faraj, P | 1 |
| Størset, E | 1 |
| Hole, K | 1 |
| Smith, G | 1 |
| Molden, E | 1 |
| Dietrichs, ES | 1 |
| Drye, LT | 1 |
| Spragg, D | 1 |
| Devanand, DP | 1 |
| Frangakis, C | 1 |
| Marano, C | 1 |
| Meinert, CL | 1 |
| Mintzer, JE | 1 |
| Munro, CA | 1 |
| Pelton, G | 1 |
| Pollock, BG | 1 |
| Porsteinsson, AP | 1 |
| Rabins, PV | 1 |
| Rosenberg, PB | 1 |
| Schneider, LS | 1 |
| Shade, DM | 1 |
| Weintraub, D | 1 |
| Yesavage, J | 1 |
| Lyketsos, CG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease[NCT00898807] | Phase 3 | 186 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CMAI examines several agitated behaviors including verbal, physical agitation, and other behaviors. Sub-items are summed. Range is 14-70. Higher scores indicate more severe symptoms. (NCT00898807)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Citalopram and Psychosocial Intervention | 27.7 |
| Placebo and Psychosocial Intervention | 28.7 |
"Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in agitation(CGIC) accesses clinically significant change in agitation. A trained clinician, blind to treatment assignment, uses a 7-point Likert scale to rate change of each patient along a continuum from marked improvement(1), no change(4), and marked worsening(7). A number of aspects of the agitation is considered such as emotional agitation, mood liability/distress, psychomotor agitation, verbal aggression, and physical aggression. Range is 1-7." (NCT00898807)
Timeframe: Baseline to 9 weeks
| Intervention | percentage moderate/marked improvement (Number) |
|---|---|
| Citalopram and Psychosocial Intervention | 40 |
| Placebo and Psychosocial Intervention | 26 |
NeuroBehavioral Rating Scale- Agitation(NBRS-A) assesses multiple types of psychopathology common in dementia and is based on a seven point Likert scale of increasing severity for each item(i.e., 0=not present, 1=very mild, 2-mild, 3=moderate, 4=moderately severe, 5=severe, 6=extremely severe). The NBRS agitation subscore includes NBRS 'inhibition', 'agitation', and 'hostility'. The range is 0 to 18 points. Higher scores indicate more symptoms. (NCT00898807)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Citalopram and Psychosocial Intervention | 4.33 |
| Placebo and Psychosocial Intervention | 5.26 |
NPI agitation score is based on responses from an informed caregiver involved in the patient's life. Symptom severity (1=mild, 2=moderate, 3=severe) is multiplied by frequency (1=occasionally, less than once/week; 4 = very frequently, once or more/day or continuously) to obtain the NPI agitation score.Range is 0-12. Higher scores indicate more severe symptoms. (NCT00898807)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Citalopram and Psychosocial Intervention | 7.8 |
| Placebo and Psychosocial Intervention | 8.0 |
1 trial available for citalopram and Cardiotoxicity
| Article | Year |
|---|---|
Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Cardiotoxicity | 2014 |
1 other study available for citalopram and Cardiotoxicity
| Article | Year |
|---|---|
Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients - a study based on a cohort of 19,742 patients.
Topics: Action Potentials; Adolescent; Adult; Aged; Aged, 80 and over; Cardiotoxicity; Child; Citalopram; Es | 2023 |